Anti|VEGF agents in metastatic colorectal cancer

Predictive value of VEGF gene polymorphisms for metastatic ...

Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and ...

Cetuximab as a Key Partner in Personalized Targeted Therapy for ...

The treatment of colorectal cancer has been revolutionized in recent decades by the identification of new targeted agents, particularly for metastatic ...

Targeted and immunotherapy drugs for advanced bowel cancer

together with irinotecan and 5FU chemotherapy (FOLIFIRI) · as your second treatment for advanced bowel cancer. This is in situations where your first treatment, ...

Efficacy of anti-epidermal growth factor receptor agents in patients ...

Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years · Overview · Fingerprint ...

Metastatic Colorectal Cancer in the Era of Personalized Medicine: A ...

In the past decade, the development of novel biologic agents including therapies directed against vascular endothelial growth factor and ...

Download Citation - PLOS ONE

The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer. PLOS ONE 8(10): e77117. https://doi.org ...

Colon Cancer Treatment Protocols - Medscape Reference

For patients who are not candidates for intensive therapy, single-agent 5-FU/LV, capecitabine, irinotecan, cetuximab or panitumumab, and ...

The Evolution of Biomarkers to Guide the Treatment of Metastatic ...

The chemotherapeutic agents used are the same as those used for colon cancer. Patients with nonmetastatic, resectable CRC who undergo complete ...

Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first ...

Microsatellite stable (MSS) and RAS-mutant metastatic colorectal cancer (mCRC) patients are characterized by an immunosuppressive ...

The Role of VEGF and EGFR Inhibition: Implications for Combining ...

When administered in combination with irinotecan, 5-FU, and leucovorin (IFL) for metastatic colorectal cancer, bevacizumab significantly improved patient ...

Cancer Treatment Reviews

Mechanism of action of antiangiogenic agents for the treatment of metastatic colorectal cancer. VEGF, vascular endothelial growth factor, PlGF, placental growth ...

Treatment of Metastatic Colorectal Cancer: Standard of Care and ...

Standard of care for the majority of patients is the combination of 5-fluorouracil (FU)/leucovorin (LV) with either oxaliplatin (FOLFOX) or ...

News from the FDA–new treatments for metastatic colorectal cancer

The FDA approved a new cancer treatment option for metastatic colorectal cancer. Fruzaqla (fruquintinib), a targeted therapy known as an anti-VEGF treatment, ...

Current and Novel Treatment Options for Metastatic Colorectal Cancer

Antiangiogenic Agents in mCRC: Bevacizumab. Bevacizumab is a humanized monoclonal antibody that binds to VEGF. Bevacizumab prevents binding of ...

Chemotherapy with Targeted Agents for the Treatment of Metastatic ...

Cetuximab and panitumumab are both efficacious among refractory mCRC patients with wild-type KRAS tumors. Other targeted agents, for example, the tyrosine ...

Mechanisms of Angiogenesis Inhibitors in Metastatic Colorectal ...

In the first e-learning activity of this 4-part series, Dr. Eric Van Cutsem explains the process of tumor angiogenesis, the biology of the ...

Optimising Systemic Therapy in Metastatic Colorectal Cancer

In addition to 5-FU, the available treatment modalities now include other cytotoxic agents (irinotecan, oxaliplatin, capecitabine), anti–vascular endothelial ...

Plasma Angiogenic Factors as Predictors of the Efficacy of Second ...

Colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide, and metastatic and recurrent CRC have poor prognosis.

KEYTRUDA® (pembrolizumab) - Official Site

Learn about KEYTRUDA® (pembrolizumab), an immunotherapy that works with your immune system to help fight certain cancers. Visit the patient website.

OPDIVO® (nivolumab)

... metastatic colorectal cancer. It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers. OPDIVO (10 mg/mL) and ...